-
Mabwell Bioscience Secures Deal with UNILAB for Biosimilar Humira in the Philippines
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing and supply agreement with Filipino firm UNILAB, focusing on Mabwell’s biosimilar version of AbbVie’s (NYSE: ABBV) Humira (adalimumab). According to the deal terms, UNILAB will handle the local regulatory filing and marketing efforts in the Philippines. Financial details…
-
HanchorBio and Henlius Pharmaceutical Enter Strategic Collaboration for Immunotherapies
•
Taiwan-based HanchorBio has entered into a strategic cooperation framework agreement with Shanghai-headquartered Shanghai Henlius Biotech, Inc. (HKG: 2696). The collaboration aims to combine HanchorBio’s expertise in protein engineering modification and its proprietary “Fc based multifunctional innovative biological agent (FBDB)” platform with Henlius Pharma’s fully integrated product development and commercialization capabilities.…
-
Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial
•
Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product, as the technology did not meet the overall survival (OS) endpoint in a Phase III trial for ovarian cancer. The ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial was designed to assess the efficacy of TTFields…
-
Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials
•
China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for its antibody drug conjugate (ADC), HBM9033. This ADC specifically targets human mesothelin (MSLN), a tumor-associated antigen that is upregulated in various solid tumors, including mesothelioma, ovarian, lung, breast,…
-
Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine
•
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition of Mycamine/Funguard (micafungin sodium) from Japan’s Astellas Pharma (TYO: 4503). Mycamine is the highest-selling antifungal of the echinocandin class, and while the transaction amount was not disclosed, the product generated JPY 14.2 billion (USD 105…
-
BMS Partners with Cellares for Automated CAR-T Cell Therapy Production
•
Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy developer and manufacturer Cellares to produce a CAR-T cell therapy. This collaboration will utilize Cellares’ clinical and commercial-stage manufacturing platform following a proof-of-concept technology transfer, which is expected to be completed within months. Advantages of…
-
Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification
•
A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached the primary objective of identifying a second novel target for neurodegenerative disorders. This achievement was made possible through the use of BridGene’s chemoproteomics platform, which is designed to discover and develop small molecules for undruggable…
-
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the “excellent performance,”…
